Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 3/20 | 0.33 |
| ▸ | CLK2 | P49760 | 3/20 | 0.33 |
| ▸ | CLK3 | P49761 | 3/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.30 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.30 |
| ▸ | DYRK4 | Q9NR20 | 2/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29642080 | 1.00 | CLK1 (0.33) | CLK1CLK2CLK3DYRK1ACLK4 | |
| SCHEMBL17298995 | 0.84 | EGFR (0.32) | — | |
| SCHEMBL22366931 | 0.84 | TGFBR1 (0.32) | NPC1RAB9A | |
| SCHEMBL25344123 | 0.81 | EGFR (0.40) | KDM4ENPC1RAB9AL3MBTL1SMN1; SMN2 | |
| SCHEMBL29513792 | 0.81 | EGFR (0.40) | KDM4ENPC1RAB9AL3MBTL1SMN1; SMN2 | |
| SCHEMBL724423 | 0.81 | EGFR (0.32) | — | |
| SCHEMBL3304374 | 0.76 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL12374406 | 0.74 | MAPK1 (0.39) | MAPK1 | |
| SCHEMBL1815592 | 0.74 | LPL (0.41) | ALDH1A1HSD17B10 | |
| SCHEMBL29520453 | 0.74 | LPL (0.41) | ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336738-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-10336738-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20150344469-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-12-03 | — | — | US | disclosed |
| US-20150344469-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-12-03 | — | — | US | disclosed |
| US-20150344469-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-12-03 | — | — | US | disclosed |
| US-9079891-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079891-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079891-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| EP-2619200-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2609095-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012040511-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071516-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071516-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071516-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120053210-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053210-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053210-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2012027710-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012027710-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336738-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | CLK1 1810/4885CLK2 1294/4885CLK3 3013/4885 |
| US-20150344469-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | CLK1 1810/4885CLK2 1294/4885CLK3 3013/4885 |
| US-20120071516-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | CLK1 1810/4885CLK2 1294/4885CLK3 3013/4885 |
| US-20120053210-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | CLK1 1810/4885CLK2 1294/4885CLK3 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.